<DOC>
	<DOCNO>NCT01108510</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy regimen contain cobicistat-boosted atazanavir ( ATV+COBI ) plus emtricitabine/tenofovir disoproxil fumarate ( Truvada® ; FTC/TDF ) fixed-dose combination ( FDC ) versus ritonavir-boosted atazanavir ( ATV+RTV ) plus FTC/TDF FDC HIV-1 infect , antiretroviral treatment-naive adult . Participants randomize 1:1 ratio . Randomization stratify HIV-1 RNA level ( ≤ 100,000 copies/mL &gt; 100,000 copies/mL ) screening .</brief_summary>
	<brief_title>Safety Efficacy COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate HIV-1 Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Ability understand sign write informed consent form , must obtain prior initiation study procedure Plasma HIV1 RNA level ≥ 5,000 copies/mL screen No prior use approve investigational antiretroviral drug length time Screening genotype report must show sensitivity FTC , TDF ATV Normal ECG Adequate renal function ( eGFR calculate use CockcroftGault equation ≥ 70 mL/min ) Hepatic transaminase ( AST ALT ) ≤ 5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 x ULN Males females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug . Age ≥ 18 year Life expectancy ≥ 1 year A new AIDSdefining condition diagnose within 30 day prior screen Receiving drug treatment Hepatitis C , anticipate receive treatment Hepatitis C Subjects experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Have implant defibrillator pacemaker Have ECG PR interval ≥ 220 msec Current alcohol substance use judge Investigator potentially interfere subject study compliance . A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline . Medications contraindicate use COBI , emtricitabine ( FTC ) , tenofovir disoproxil fumarate ( TDF ) , atazanavir ( ATV ) , ritonavir ( RTV ) subject known allergy excipients COBI tablet , Truvada tablet , atazanavir capsule ritonavir tablet . Participation clinical trial without prior approval sponsor prohibit participate trial . Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV 1 Infected</keyword>
</DOC>